126 results about "Leukaemia cell" patented technology

The invention discloses an application of LDLR in screening or preparing a medicine for treating acute myelogenous leukemia, the expression level of the LDLR in acute myelogenous leukemia cells is detected for the first time so as to characterize the conditions of proliferation, apoptosis, cycle and the like of the acute myelogenous leukemia cells, and the LDLR is taken as a target spot; by knocking down the expression quantity of the LDLR, the proliferation of acute myelogenous leukemia cells can be inhibited, the apoptosis of the acute myelogenous leukemia cells can be promoted, the cycle of the acute myelogenous leukemia cells can be retarded in the S phase, the in-vitro proliferation of the acute myelogenous leukemia cells can be accurately and effectively inhibited, and the application prospect is wide. A new thought and a new direction are provided for screening or preparing the medicine for diagnosing and treating the acute myelogenous leukemia.

The invention relates to application of a DDX39B protein inhibitor in preparation of acute leukemia treatment medicines, and belongs to the technical field of biological medicines. In order to solve the problems of single acute leukemia treatment scheme and lack of novel medicines at present, the invention provides application of a DDX39B protein inhibitor in preparation of acute leukemia treatment medicines. Targeted inhibition of DDX39B can significantly hinder proliferation of leukemia cells, promote apoptosis and differentiation of cells, retard the process of cell cycles, delay disease progression in vivo and prolong the lifetime of model animals. On the basis of an RNA (Ribonucleic Acid) binding pocket structure of DDX39B, through high-throughput drug screening, the small molecule compound HMU-4051C is firstly identified as a DDX39B targeted inhibitor to effectively kill leukemia cells, and a new application of the DDX39B protein inhibitor in preparation of acute leukemia treatment drugs is developed.

A human chronic myeloid leukemia cell line and the use thereof. The human chronic myeloid leukemia cell line is the first cell line internationally established from chronic-phase leukemia cells of chronic myeloid leukemia, and was named human chronic myeloid leukemia cell YYXY-M6, which was deposited at the China Center for Type Culture Collection (Wuhan University, Wuhan, China) on July 24, 2023, under the deposit number of CCTCC NO: C2023219. The leukemia cell line exhibits primitive cell morphology and has three karyotypes, i.e. t(6:11)(q25:q23), del(11)(q23) and normal karyotype (46, XX); is BCR-ABL gene-negative; has good in-vitro proliferation ability; can be used as cellular material for the study of the mechanism of occurrence and development of the chronic phase of chronic myeloid leukemia, from the chronic phase thereof to the blastic phase thereof, and of BCR-ABL gene-negative chronic myeloid leukemia, and for the in-vitro study of individualized treatment; and can also be used for both in-vitro and in-vivo studies of drug screening and evaluation for the chronic phase of chronic myeloid leukemia, from the chronic phase thereof to the blastic phase thereof, and BCR-ABL gene-negative chronic myeloid leukemia, providing guidance for clinical medication.

The invention discloses a combined treatment medicine for acute myelogenous leukemia. The combined treatment medicine is prepared from vinaclaria, azacitidine and aclarithromycin. The medicine is applied to preparation of an acute myelogenous leukemia cell proliferation inhibitor; the medicine is applied to preparation of an acute myelogenous leukemia cell apoptosis inducer. The three medicines are combined to achieve a synergistic effect: the three medicines have a synergistic anti-tumor effect instead of a simple superposition effect, and a new combined medication mechanism is a result obtained through laboratory research and an initial effect of clinical application. The subsequent consolidation treatment scheme may also be used for part of initially treated patients with acute myelogenous leukemia, which are not suitable for enhanced chemotherapy or intense intense treatment by using targeted drugs, and relapse / refractory patients with acute myelogenous leukemia, and a better treatment scheme can also bring new hope and dawn to more patients.

The present invention relates to a system and a method for measuring and analyzing minimal residual disease (MRD) in pediatric B-cell precursor acute lymphoblastic leukemia (B-ALL) using multiparameter flow cytometry (MPFC). The invention finds application in clinical diagnostics and hematology-oncology for quantifying MRD in B-ALL patients with high sensitivity and specificity, needed for risk stratification, monitoring treatment response, and informing therapeutic decisions. The system comprises interconnected subsystems including an acquisition subsystem with an MPFC instrument, a control and file generation subsystem, and an analytical subsystem. The analytical subsystem incorporates modules for sequential data reduction, automated data cleaning, automated unsupervised data clustering, and interactive cluster analysis. Key advantages include high MRD detection sensitivity (e.g., 10⁻⁵ or 0.001%) and high specificity, without reliance on reference samples or supervised machine learning models, making it applicable in laboratories with different measuring equipment and using different panels of antibodies for identification of leukemic cells.

The invention relates to application of PWWP2B as a target spot in preparation of leukemia treatment drugs, and belongs to the technical field of biological medicines. In order to solve the problem that a traditional AML treatment target is lack of tumor specificity and is difficult to meet clinical requirements, the invention provides application of PWWP2B as a target in preparation of leukemia treatment drugs. The invention proves that PWWP2B is highly expressed in acute myelogenous leukemia cells, and the PWWP2B as a molecular marker can accurately distinguish acute myelogenous leukemia from normal healthy people or non-leukemia patients. In-vivo and in-vitro experiments prove that by knocking out PWWP2B, proliferation and clone formation of acute myelogenous leukemia cells can be remarkably inhibited, differentiation and apoptosis of the acute myelogenous leukemia cells are promoted, and activity of leukemia cells in a patient body is inhibited. The invention discloses the new application of the small molecule compound EZM0414 in treating acute myelogenous leukemia for the first time, and the synergistic interaction of the small molecule compound EZM0414 and a methylase inhibitor can be realized.

The invention relates to a management method and system for a leukemia cell morphology intelligent recognition microscopic device, and solves the problems that imaging quality fluctuates, suspicious cell recognition precision is limited, and clinical efficient standardization requirements are difficult to meet. Extracting sample features and calling a parameter library according to rules to select optimal scanning and imaging parameters for initialization; starting an X / Y-axis motor according to the parameters, and correcting the deviation by combining an anti-interference rule and an encoder; z-axis dual-stage focusing is carried out after stable stopping, and an FPGA time sequence control camera carries out acquisition; aI judgment results are sent to images, suspicious cells are delineated and then positioned, and high-power lens re-focusing collection and AI recognition are carried out. The method has the advantages that sample adaptation and positioning precision is improved, suspicious cell recognition is optimized, and detection efficiency and precision are improved.

The present invention discloses a small molecule inhibitor nanoparticle based on polyamino acid, which is composed of polyethylene glycol b ‑Poly(4‑boron‑L‑phenylalanine‑ What Specifically, polyethylene glycol- b ‑Poly(4‑boron‑L‑phenylalanine‑ What A solution of a β-L-tyrosine (L-tyrosine) copolymer and a drug solution were added dropwise to a buffer solution. After the addition was complete, dialysis was performed to produce polyamino acid-based small molecule inhibitor nanoparticles. These nanoparticles exhibited excellent drug co-encapsulation and stability, and rapidly released the drug in an acidic / hydrogen peroxide / enzyme environment, achieving synergistic killing of leukemia cells and significantly inhibiting leukemia cell infiltration in organs such as the bone marrow, spleen, and liver. The nanomedicine designed in this invention exhibits high drug loading efficiency, excellent stability, and trigger-responsiveness. Furthermore, this intelligent nanomedicine boasts a simple structure, adjustable drug combinations, high safety, and strong synergistic efficacy, making it readily applicable to cancer treatment.

The present invention discloses a modified chimeric antigen receptor T cell, its preparation method, and its use. The present invention prepares cells, such as chimeric antigen receptor T cells, modified with a hydrophobic two-dimensional sheet material. Compared to simple chimeric antigen receptor T cells, these cells can bind to more leukemia cells, enhancing their recognition and killing abilities. Furthermore, the nanomaterial's high specific surface area provides space for drug loading, enabling the combination of CAR T cells with other therapies.

The application discloses a kind of trichoderma fermentation processing indigo blue method, the product obtained and application.The method includes: preparation trichoderma seed liquid;After primary indigo blue sterilization, access seed liquid, fermentation 5-9 days under 25-30 DEG C, 120-180 rpm, avoid light, obtain secondary processing indigo blue.The application first utilizes trichoderma to carry out biological transformation to indigo blue, can significantly improve the content of its key anti-tumor component indigo carmine with specificity, and the increase is more than 150%.In vitro anti-tumor experiment shows that the inhibitory activity of secondary processing indigo blue prepared by the application to human leukemia K562 cells and human colon adenocarcinoma cell SW480 cell is significantly better than ordinary indigo blue.The product of the application can be used for preparing medicine for preventing and / or treating leukemia, colon adenocarcinoma, process controllable, suitable for industrialized production, and provides a new way for developing efficient indigo blue anticancer new drug.

The invention provides an application of a gemmarane type sesquiterpene lactone compound in preparation of an antitumor drug. The gemmarane type sesquiterpene lactone compound disclosed by the invention has a relatively strong inhibition effect on proliferation of tumor cells, especially leukemia cells, and is more particularly most sensitive to human erythroleukocyte leukemia cells (HEL).

The invention discloses a compound containing an artemisinin similar structure or a pharmaceutical salt thereof, and the structural general formula is as follows: # imgabs0. The compound containing the artemisinin similar structure, provided by the invention, has a relatively obvious proliferation inhibition effect on solid tumor cells such as lung cancer A549, colon cancer HCT116 and liver cancer HepG2; wherein the high-activity compound has an excellent proliferation inhibition effect on leukemia cells HL-60 and MV4-11, is better than a marketed drug SAHA, and can be used as an anti-tumor candidate drug for deeper research.

The invention discloses a targeting nanoscale particle, a targeting cell as well as a preparation method and application of the targeting nanoscale particle and the targeting cell. Wherein the outer surface of the targeting cell is combined with a targeting nano-scale particle, the targeting nano-scale particle is formed by mutually connecting a plurality of proteins through a first combination part, the targeting nano-scale particle further comprises a second combination part, and the targeting nano-scale particle is combined with the outer surface of the target cell through the second combination part. In an exemplary embodiment, the targeting nanoscale particles can promote interaction between the chimeric antigen receptor T cells and the leukemia cells by being simultaneously combined with the chimeric antigen receptor T cells and the leukemia cells, and then the chimeric antigen receptor T cells are promoted to recognize and kill the leukemia cells. In addition, a space is provided for loading of chemotherapeutic drugs by a protein internal cavity in the targeting nanoscale particles, and combined therapy of the chimeric antigen receptor T cells and other therapies is realized while the drugs are loaded.

The invention discloses a protein ADGRE2-targeted acute myelogenous leukemia treatment medicine and application, and relates to the technical field of biomedicine. The invention provides an application of a drug targeting protein ADGRE2 in preparation of a drug for preventing and / or treating acute myelogenous leukemia. The protein ADGRE2 is highly specifically expressed on the surface of an acute myelogenous leukemia cell membrane, and the targeted protein ADGRE2 can inhibit the proliferation ability and migration ability of acute myelogenous leukemia cells and promote the apoptosis of the acute myelogenous leukemia cells. Meanwhile, the protein ADGRE2 can be used as an effective drug target for CAR-T cell therapy, guides the development of novel CAR-T cells, and is expected to promote the novel target CAR-T cell therapy for acute myelogenous leukemia to make a major breakthrough.

The invention discloses a pharmaceutical composition for inducing leukemia cell copper death and application thereof, and relates to the technical field of tumor cell apoptosis. The active ingredients of the pharmaceutical composition are oleanolic acid and illlisemom. It is found for the first time that oleanolic acid can significantly up-regulate expression of a copper death key regulatory factor FDX1, when oleanolic acid is used in combination with a copper ion carrier Ilismor, a large synergistic effect can be generated through an FDX1 / DLAT axis, leukemia cells are significantly induced to generate copper death, and therefore in-vitro proliferation and in-vivo tumor forming ability of the leukemia cells are effectively inhibited. The composition provides a new drug development strategy with a clear mechanism for treatment of leukemia, especially drug-resistant leukemia.

The present invention discloses the use of piperine or its derivatives, relating to the field of pharmaceutical technology. The present invention utilizes natural piperine as a precursor compound and chemically modifies it to obtain a series of novel piperine derivatives. Pharmacodynamic evaluations in leukemia, ovarian cancer, and pancreatic cancer cell models in vitro and in vivo revealed that several novel piperine derivatives inhibit tumor cell proliferation, induce tumor cell apoptosis, and promote leukemia cell differentiation. The present invention provides a group of compounds with novel structures. The synthetic route employed utilizes green chemistry reactions, making them more environmentally friendly and more economical in terms of raw materials. These compounds can be used to develop new drugs for the treatment of leukemia, ovarian cancer, and pancreatic cancer.

The invention discloses a compound for targeted ubiquitination degradation of USP7 protein, and a medicinal composition and application thereof. The structural formula of the E3 ubiquitin ligase complex is as shown in formula I. A is a specific protein ligand in the E3 ubiquitin ligase complex; l is a bivalent linking group between a USP7 protein small molecule ligand and a specific protein ligand in an E3 ubiquitin ligase complex. The protein degradation chimera has the activity of inhibiting USP7 protein and the activity of degrading USP7 protein, and can effectively inhibit malignant proliferation of acute lymphatic leukemia cells, so that the protein degradation chimera can be used for related diseases with abnormal expression of USP7 protein.

The invention relates to the technical field of medicines, in particular to an enantiomer-atesane type diterpenoid compound as well as a preparation method and an application of the enantiomer-atesane type diterpenoid compound. The enantiomer-atesane diterpenoid compound disclosed by the invention is derived from plants, has anti-tumor activity, has cytotoxicity to human leukemia cells, human liver cancer cells and human cervical cancer cells, and is relatively good in inhibitory activity. Wherein the compound 3 has the best effect, the IC50 values of the compound 3 to three human tumor cells are 7.5 + / -1.2 micromole per liter, 9.8 + / -1.0 micromole per liter and 10.1 + / -0.9 micromole per liter respectively, and the activity of the compound 3 is equivalent to that of a positive control drug mitomycin. Particularly, the compound 3 also has good cytotoxicity to drug-resistant liver cancer cells (Huh7-LR cells), and the IC50 value of the compound 3 is 9.6 + / -1.1 micromole per liter. The compound 3 shows huge potential as a lead compound by virtue of the novel chemical structure and potent cytotoxicity shown in various cell lines.

Monitoring active disease or progressive disease under therapy in chronic lymphocytic leukemia (CLL) represents a challenge to earlier and better adapt therapeutic strategy, notably in the era of targeted therapies in which minimal residual detection or mutations are sometimes not associated to poor clinical outcome. By following CLL patients before treatment (Binet stages A and B / C) or during targeted therapy, the Inventors developed a new flow cytometric method, based on CD69, CD49d, CD20 and CD279 expression at the surface of CD19+ / CD5+ B leukemic cells. Analyses of these markers alone or in combination show that CD69 / CD49d / CD20 / CD279 co-expression (quadruple population, QP) > 0.5% is the best criterion predicting CLL active disease or progression under therapy. This new flow cytometry immunophenotyping could help clinicians to monitor CLL evolution and quickly adapt their therapeutic strategy. Accordingly, the present invention relates to an ex vivo method for predicting active Chronic Lymphocytic Leukemia (CLL) or progressive CLL under therapy in a subject suffering from CLL, comprising the step of quantifying a population of CD69+ / CD49d+ / CD20+ / CD279+ cells in a sample obtained from the subject.

The present invention relates to a specimen analyzer and a specimen analysis method, which make it possible to screen CML patients in the early stage of onset, which are difficult to implement in a blood cell counting test. A specimen analyzer includes: a measurement unit that acquires optical information of cells by irradiating a plurality of diffracted lights generated by light incident on a diffractive optical element to the cells contained in a specimen; and an analysis unit that analyzes the optical information obtained by the measurement unit by means of an artificial intelligence algorithm, thereby acquiring information on leukemia cells contained in the specimen.

The application discloses a DNA nanocage probe for leukemia cell multi-specific membrane protein logic circuit analysis, a kit and a method thereof, and realizes in-situ imaging analysis on three target membrane proteins by using a probe of a cross-section octahedral DNA nanocage main frame, stable structure, and designing a three-specific recognition biological computing DNA molecule logic gate based on a nucleic acid aptamer (Sgc4f, TC01, Sgc8c), which provides a new tool and idea for early diagnosis of tumors and biomedical application of the DNA molecule logic gate in a complex cell system.

The invention belongs to the technical field of medicines, and particularly relates to application of a compound targeting DOCK1 protein in preparation of a medicine for treating leukemia. The compound capable of being combined with the DOCK1 protein is obtained through virtual screening and a surface plasmon resonance experiment; cell experiments verify that the related compounds can inhibit the survival rate of acute myelogenous leukemia cells, induce apoptosis of the acute myelogenous leukemia cells and weaken the colony ability of the acute myelogenous leukemia cells. The compound provided by the invention inhibits proliferation and development of acute myelogenous leukemia cells, reduces damage to normal tissues and improves tolerance of patients by targeting DOCK1 protein and inhibiting the activity of the DOCK1 protein, and provides a new strategy for treatment of acute myelogenous leukemia.

The invention discloses an enzyme response magnetic resonance imaging nanoprobe as well as a preparation method and application thereof. The enzyme response magnetic resonance imaging nanoprobe comprises a metal nanoparticle with a surface functional group A as an imaging basic unit, and a polypeptide sequence with functional groups B at two ends as a cross-linking agent and an enzyme response unit, the enzyme response magnetic resonance imaging nano-probe is a metal nano-particle cross-linked body formed by cross-linking the metal nano-particles through a polypeptide sequence. The enzyme response magnetic resonance imaging nanoprobe disclosed by the invention can be specifically cut by a high-expression enzyme in a cell differentiation process to form monodispersed metal nanoparticles, so that signal transformation is presented on magnetic resonance imaging; meanwhile, the enzyme response magnetic resonance imaging nanoprobe can establish effective association among the probe existence form, the cell state and the imaging signal, and is used for tracking the directional differentiation process of mesenchymal stem cells, neural stem cells and promyelocytic leukemia cells in real time.

The invention belongs to the technical field of biological medicines, and discloses application of protein nano-selenium in preparation of a medicine for preventing and treating acute monocyte leukemia. The protein nano-selenium prepared by the invention has better stability and safety than inorganic nano-selenium prepared by a traditional method, has higher bioavailability than selenium yeast tablets and inorganic nano-selenium after oral administration, has stronger capability of promoting ferroptosis of leukemia cells, and has a better treatment effect on acute mononuclear leukemia.

The invention relates to a halogenated kaurane diterpenoid compound, and belongs to the technical field of natural product chemistry and medicinal chemistry. In the prior art, separation and purification of halogenated kaurane diterpenoid compounds from pteris semipinnata plants have the problems of low efficiency and insufficient purity, and deep research and application of the active ingredients are restricted. The novel compound is successfully obtained from a pteris semipinnata ethanol or methanol extract through systematic extraction and a multi-step chromatographic separation technology, the chemical structure of the novel compound is confirmed to be 16R-17-chloroethyl-1 beta-hydroxy-ent-kauran-19-acid through nuclear magnetic resonance and high-resolution mass spectrometry, and the structural formula is shown in the specification. The compound shows proliferation inhibition activity on K562 leukemia cells, A549 lung cancer cells, MDA-MB-231 breast cancer cells, SW480 colon cancer cells and human lung cancer paclitaxel drug-resistant strains A549 / Taxo in an in-vitro experiment, so that the compound can be used for preparing antitumor drugs.

The application discloses an enzyme-responsive magnetic resonance imaging nano probe and a preparation method and application thereof. The enzyme-responsive magnetic resonance imaging nano probe comprises a surface functional group A metal nanoparticle as an imaging basic unit, and a functional group B polypeptide sequence as a crosslinking agent and an enzyme-responsive unit; and the enzyme-responsive magnetic resonance imaging nano probe is a metal nanoparticle crosslinking body formed by crosslinking the metal nanoparticle through the polypeptide sequence. The enzyme-responsive magnetic resonance imaging nano probe can be specifically cut by an enzyme highly expressed in a cell differentiation process, and forms a monodispersed metal nanoparticle, so that a signal change is presented on magnetic resonance imaging. Meanwhile, the enzyme-responsive magnetic resonance imaging nano probe can establish an effective correlation among a probe existing form, a cell state and an imaging signal, and is used for real-time tracking of a directional differentiation process of mesenchymal stem cells, neural stem cells and promyelocytic leukemia cells.

This invention provides a method for preparing a non-natural humanized chimeric anti-human CD45RA antigen receptor, which specifically binds to the human CD45RA antigen by expressing CAR protein on T cells. Based on a humanized 3A4 antibody, this invention constructs a lentiviral expression vector pLenti / Hu3A4-4-1BB-3ζ. Compared with murine CAR, the humanized CAR significantly reduces immunogenicity, noticeably decreases the production of anti-scFv antibodies, and avoids the HAMA reaction. Research results show that Hu3A4CAR-T cells can specifically bind to the CD45RA-highly expressing myeloid leukemia cell line KG1a. Hu3A4CAR-T cells can target and kill 3A4-positive cell lines and leukemia cells, alleviate the human anti-mouse antibody response, and significantly reduce the production of anti-scFv antibodies, thereby ensuring the CAR's killing activity.

The invention provides an individualized drug screening method for leukemia based on CD45 monoclonal antibody enrichment. The method comprises the following steps: collecting a bone marrow extract sample or a peripheral blood sample, separating to obtain a mononuclear cell, labeling the mononuclear cell from a patient by adopting a human CD45 antibody, enriching a leukemia cell population through the CD45 monoclonal antibody based on a CD45 / SSC gating method, adding a leukemia primary drug sensitivity detection culture medium, and detecting the cell activity inhibition condition after adding a corresponding drug to act. The leukemia cell population is enriched through the CD45 monoclonal antibody based on CD45 / SSC, the cells are subjected to drug sensitivity detection to screen out leukemia individualized drugs, interference of normal cells in different quantity proportions in a source sample on leukemia drug sensitivity is eliminated, and response of the source leukemia cells to the drugs can be reflected more truly and visually. The rapid and accurate leukemia individualized drug screening method has important significance for improving the treatment outcome of acute myelogenous leukemia.

The invention provides a use of a marker or a combination thereof in preparation of a product for prediction, diagnosis or auxiliary diagnosis of measurable residual diseases, the measurable residual diseases occur after clinical complete remission of acute myelogenous leukemia patients, and the marker or the combination thereof comprises a C-X-C chemokine receptor 4 gene. According to the method, a multi-parameter flow sorting technology is adopted, leukemia cell populations are separated from bone marrow samples of patients in the first diagnosis stage and the AML MRD stage, and a sufficient number of residual disease cells are successfully captured through a single cell transcriptome sequencing technology. The CXCR4 low-expression cell is identified to be capable of being used as a common marker of an MRD cell, and is verified in a clinical AML patient specimen. And an innovative scheme is provided for MRD monitoring of AML patients lacking clear molecular markers. And meanwhile, a CXCR4 low-expression cell is provided as a function substitution model of the MRD cell, so that the technical limitation of insufficient residual cells in the traditional research is broken through, and a reliable research system is established for systematically exploring the biological characteristics of the MRD cell.

This invention relates to the application of PWWP2B as a target in the preparation of drugs for the treatment of leukemia, belonging to the field of biomedical technology. To address the problem that traditional AML treatment targets lack tumor specificity and fail to meet clinical needs, this invention provides the application of PWWP2B as a target in the preparation of drugs for the treatment of leukemia. This invention demonstrates that PWWP2B is highly expressed in acute myeloid leukemia (AML) cells, and as a molecular marker, it can accurately distinguish AML from healthy individuals or non-leukemia patients. In vivo and in vitro experiments demonstrate that knocking out PWWP2B can significantly inhibit the proliferation and colony formation of AML cells, promote their differentiation and apoptosis, and inhibit the activity of leukemia cells in patients. This invention also reveals for the first time a novel use of the small molecule compound EZM0414 in the treatment of AML and its synergistic effect when used in combination with methyltransferase inhibitors.